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Abstract
We review an emergingmicroﬂuidics-based toolkit for single-cell functional
proteomics. Functional proteins include, but are not limited to, the secreted
signaling proteins that can reﬂect the biological behaviors of immune cells or
the intracellular phosphoproteins associated with growth factor–stimulated
signaling networks. Advantages of the microﬂuidics platforms are multiple.
First, 20 or more functional proteins may be assayed simultaneously from
statistical numbers of single cells. Second, cell behaviors (e.g., motility) may
be correlated with protein assays. Third, extensions to quantized cell popu-
lations can permit measurements of cell–cell interactions. Fourth, rare cells
can be functionally identiﬁed and then separated for further analysis or cul-
turing. Finally, certain assay types can provide a conduit between biology
and the physicochemical laws. We discuss the history and challenges of the
ﬁeld then review design concepts and uses of the microchip platforms that
have been reported, with an eye toward biomedical applications. We then
look to the future of the ﬁeld.
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1. INTRODUCTION
Over the past 25 years, microﬂuidic techniques (1) have emerged for the manipulation, sorting,
and analysis of small biological samples, ranging frommicroliters of blood (2) to single cells (3, 4).
On-chip assays range from cell counting to molecular measurements, with applications that span
broadly across the ﬁelds of biology and biomedicine. Many of these microchip tools have been ex-
tensively reviewed in the recent literature (5–11). One of the newer technologies to emerge, and to
be adapted to microchip formats, is single-cell functional proteomics. Functional proteins include
the secreted cytokines, chemokines, proteases, and granulocytes that are commonly associated
with immune cell function (12) but are also observed for other cell types. Functional proteins also
include catalytically active (e.g., phosphorylated) kinases and associated effector proteins. This
protein class comprises the intracellular signaling cascades (13), which are often hyperactivated
in cancer cells and are consequently targeted by anticancer therapies (14). In their active states,
such proteins have functional consequences that can be associated with the various hallmarks of
cancer (15, 16). The kinetics, abundances, and statistical distributions of functional proteins often
set them apart from their nonfunctional counterparts. Thus, we begin in Section 2 with a discus-
sion on a few representative examples of functional proteins, with an eye toward identifying those
practical issues associated with single-cell assays.
The ﬁrst reports of microchip platforms for single-cell functional proteomics appeared just
within the past decade (17–20). However, the technology has evolved rapidly such that several
clinically relevant and uniquely enabled applications have been reported. This suggests that, in the
near future, at least some of these platforms will emerge as clinical tools for helping guide patient
care. This rapid advance is due, in large part, to the long history of single-cell proteomics, which
originated with techniques such as enzyme-linked immunosorbent spot (ELISpot) (21) and a host
of cytometry methods. These techniques, which continue to serve as the gold standard for most
single-cell proteomics assays, have guided the development of microchip-based technologies and
have deﬁned many of the important biological problems for investigation. In Section 3, we discuss
some of that history and how it has inﬂuenced the development of the microchip platforms that
are the subject of this review.
Microchip platforms for single-cell functional proteomics are based on either staining and
imaging ﬁxed cells (22) or putting live cells into small environments such as microbubbles (18)
or microchambers (17, 20) for analysis. Each of these tools has distinct advantages and disad-
vantages, and a few have advanced toward being applied to addressing biomedical or clinical
problems. Such applications, which imply signiﬁcant scientiﬁc and engineering demands, have,
in fact, served as technology drivers. We list those demands here. (a) Clinical applications imply
single-use microchips, and thus the chips must be inexpensive to fabricate in at least moderate
throughput, and in a highly reproducible manner. (b) In single-cell biology, statistical numbers
of single cells (hundreds to thousands) must be analyzed for any given assay to generate a mean-
ingful result (23). (c) The proteomics (and other on-chip) assays must be robust and highly re-
producible so that meaningful comparisons can be made between data sets collected across time
points, patient samples, assay conditions, etc. (d ) For many problems, the relevant functional
proteins are present at low abundance (102–104 copies per cell). As a general rule, primary cells
(direct from blood or tissue) contain signiﬁcantly lower copy numbers of a given protein than
do cultured cells. Thus, assay sensitivity is an important factor. Demands a and b largely de-
scribe engineering challenges, whereas demands c and d have mostly been addressed through a
combination of surface chemistry approaches, coupled with advances in biomolecular labeling
chemistries. In Section 4, we review the basic microﬂuidics platforms that have been reported.
Because this is an analytical chemistry review, we emphasize quantitative measurement challenges
276 Yu et al.
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and the engineering and surface chemistry solutions that are permitting those challenges to be
addressed.
In Section 5, we highlight applications in which microchip-based single-cell proteomics tools
are providing unique and useful advantages. One major area has been in the design of platforms
that integrate different assays, such as measurements of cell motility (24) or immune cell activation
(25), correlatedwith functional proteomics assays from those same cells. A second area has been the
ability to execute proteomics assays on quantized cell populations (i.e., 1, 2, 3. . .cells). These allow
for a detailed analysis of speciﬁc cell–cell interactions (26, 27). A third area has been with regards
to the numbers and types of functional proteins that can be assayed per cell, as well as the level
of absolute quantitation and sensitivity that can be achieved (28). These capabilities open up new
classes of systems for investigation. One such example involves the intracellular phosphoprotein
signaling networks within cultured or primary cancer cells and the inﬂuence that targeted drugs
can have on those networks (29, 30).
Finally, in Section 6, we look toward the future. Some of our projections are straightforward,
such as anticipating the increase in technical capabilities of the microchip platforms, including the
integration of multiple omic-type assays on the same single cells. An area that is less deﬁned, but
very important, involves the development of a discovery-based single-cell proteomics approach.
All existing single-cell proteomic methods rely on antibodies and as such are targeted toward
measuring the levels of speciﬁc proteins, the identities of which are predetermined. An approach
that can go beyond this limitation, perhaps involving mass spectrometry (31), is a grand challenge
of the ﬁeld.
An area of single-cell functional proteomics that is omitted from this review is optical studies
that utilize genetically modiﬁed cells as a means of generating in situ optical readouts of protein
expression levels (see, e.g., 23, 32, 33). Such investigations are revealing a rich biology that is
highly relevant to many of the basic concepts stressed here.
2. DETECTING FUNCTIONAL PROTEINS FROM SINGLE CELLS:
RELEVANT PARAMETERS
Functional proteins are often transient and low-abundance targets for measurement. They are
typically generated, released, and/or activated following stimulation, and their production is often
the end result of a series of stochastic events. In other words, they are the opposite of housekeeping
proteins (such as actin) that are present in abundant and reasonably stable concentrations. Thus,
experimental designs for capturing functional protein levels from single cells should take into
account several factors, including (a) the expected number of copies that are produced by individual
cells; (b) the stimulation conditions required to generate such proteins; (c) the expected variance
in protein number as measured across many single cells; and (d ) the kinetics associated with that
production, which can often compete with kinetics for the degradation of that same protein.
Additional relevant factors include the cell type and cell phenotype, whether the cell is from
culture or is a primary cell, and the history of the cell prior to analysis. Providing a comprehensive
description of these factors is well beyond the scope of this review. However, it is instructive
to consider a few illustrative examples, which are provided in Table 1. Listed in the table are
three secreted proteins, including the cytokine tumor necrosis factor-α (TNF-α), the cytotoxic
granule Granzyme B (GB), the secreted growth factor [vascular epithelial growth factor (VEGF)],
a phosphorylated (p-) receptor tyrosine kinase (RTK) [epidermal growth factor receptor (EGFR)],
and a cytoplasmic phosphokinase [p-extracellular signal-regulated kinase (ERK)].
The ﬁrst entry is TNF-α, which, along with interferon-γ (IFN-γ), often provides a marker
for immune cell activation. TNF-α is produced by numerous cell types following speciﬁc
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Table 1 Descriptions and experimentally relevant parameters for selected functional proteinsa,b
Protein Description Copy numbers per cell and basic quantitative description
TNF-α This is a cytokine secreted by many (mostly immune)
cell types (e.g., macrophages, T cells, and neurons)
following cell stimulation. It is involved in systemic
inﬂammation and stimulates acute phase reaction
(109). TNFα is a drug target for certain
autoimmune diseases.
It requires cell stimulation. Tumor antigen-speciﬁc CD8+ T
cells secrete from <101 to >105 copies over 12 h (Figure 1).
A secretion rate of 10 copies sec−1 was measured from
inﬂuenza antigen-speciﬁc CD4+ T cells (25).
GB This is a serine protease (enzyme) present in
cytotoxic T lymphocyte and NK cell granules.
Following cell stimulation, GB induces apoptosis in
the target cell (110).
Commercial protein is not readily available, so an absolute
calibration of assayed protein levels is not possible. Copy
numbers secreted from tumor antigen-speciﬁc CD8+ T cells
over a 12-h period poststimulation span a range of 105 across
individual cells (28).
p-EGFR This is a cell surface RTK that is related to
HER2/c-neu and other RTK drug targets.
Stimulation by TGF-α or EGF phosphorylates
EGFR. p-EGFR dimerizes and then activates
signaling through many phosphoprotein pathways
(111).
An average of 2 × 103 copies of phosphorylated wild-type
EGFR per cell was present in model brain cancer cells
containing the EGFR variant III oncogene (U87 EGFRvIII
cells). The copy numbers range from 102 to near 105 (29).
(See entry below for phosphorylation kinetics description.)
p-ERK p-ERK is a cytoplasmic kinase that is also called
classical MAPK. It is activated by growth factors,
hormones, and other signals. Disruption of the
ERK signaling pathway is common in cancers (14).
2,000–30,000 copies of p-ERK are produced by
nonstimulated model brain cancer (U87) cells. Between
10,000–100,000 copies are present in those same cells
following EGF stimulation (29). Phosphorylation occurs
within 2–3 min of stimulation. In the absence of stimulation,
phosphoprotein levels begin to decay within ∼20 min.
VEGF This is a secreted growth factor. It is an oncology and
ophthalmology drug target (112).
Between 103 and 105 copies were secreted from model U87
EGFRvIII brain cancer cells over a 7-h period (30).
aSee cited literature for the measurement details.
bAbbreviations: EGF(R), epidermal growth factor (receptor); ERK, extracellular signal-regulated kinase; GB, Granzyme B; HER2/c-neu, human
epidermal growth factor receptor 2; MAPK, mitogen activated protein kinase; RTK, receptor tyrosine kinase; TGF, transforming growth factor;
TNF, tumor necrosis factor; VEGF, vascular epithelial growth factor.
stimulations, so any single-cell assay should involve an activation step or be designed to probe
otherwise activated cells. TNF-α can be produced in large copy numbers (>106 per cell within
a 6-h period) and relatively quickly (10 per second). However, often only 10% of the total cell
population will produce signiﬁcant amounts of this protein. This low fraction of secretors may
be associated with the relationship of the individual cells to their positions in the cell cycle
(34), the stochastic nature of biology, the prior history of the cells, etc. The low fraction of
protein-producing cells is just one of the many factors that illustrate the need to assay statistically
signiﬁcant numbers of cells. Such statistics are straightforward for ﬂow cytometry but must be
speciﬁcally designed into any microﬂuidics platform. Figure 1 provides one-dimensional scatter
plots showing how the average level and variance of a panel of secreted proteins, including
TNF-α, differs among ﬁve immunotherapy cancer patients. These data were collected on a
single-cell barcode chip (SCBC) (see Section 4) and illustrate the value of absolute calibrations.
Those calibrations permit comparisons across different proteins and patients in this ﬁgure but also
across time points, drug treatments, etc. Such calibrations are tough to do using ﬂow cytometry.
They rely on the availability of standard proteins and as such should also be interpreted with
some caution. For example, proteins from a primary source may have different posttranslational
modiﬁcations relative to the standard protein, and this can inﬂuence assay sensitivity.
278 Yu et al.
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Figure 1
Scatter plots of the copy numbers per cell of three cytokines and CCL-4 assayed from single tumor
antigen-speciﬁc CD4+ and CD8+ T cells collected from ﬁve cancer patients participating in an
immunotherapy trial. Each dot is a single-cell assay. The measurement error is approximately 10%, and thus
the distribution of protein levels reﬂects immune system heterogeneity which, for a given patient and by this
metric, can span many orders of magnitude. Absolute calibrations were done with commercially available
standard proteins. These data were collected and processed according to protocols outlined in Reference 28.
Abbreviations: CCL, chemokine C-C motif ligand; CD, cluster of differentiation; IFN, interferon;
TNF, tumor necrosis factor.
GB is secreted by certain immune cell phenotypes for cell killing functions. GB is not always
commercially available (such is the case for many proteins), and this can preclude assay calibration.
However, one can estimate the statistical variance of the abundance distribution across a relevant
cell population if the immunoassay signal levels are in the linear regime. For a ﬂuorescence assay,
that is the range within a log-log plot of themeasured ﬂuorescence versus concentration that yields
a straight line. The variance in protein abundance across many otherwise identical single cells will
typically be high for almost any functional protein (Figure 1), but the details of that variance, and
how it changes in response to some perturbation, contains biological information (see Section 5).
For a protein such as GB, most activated cells will not secrete GB at levels much above baseline,
but the cells that are active secretors can be extremely active—effectively producing a bimodal
population of secretors and nonsecretors.
The third protein in Table 1 is an activated (phosphorylated) membrane receptor kinase,
p-EGFR, and the fourth is an activated cytoplasmic phosphokinase, p-ERK. Such kinases can
www.annualreviews.org • Single-Cell Functional Proteomics 279
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typically be phosphorylated at any number of sites—not all of which signiﬁcantly increase enzyme
activity. Monoclonal antibodies that exhibit avidity for speciﬁc phosphorylated residues of speciﬁc
proteins are used for detecting activated (and thus functional) kinases in both single-cell and bulk
assays. The average number of copies of p-EGFR per cell (for model brain cancer cells) is approx-
imately 2,000. Of course, if the cells are ﬁxed, made permeable, and then antibody-stained for the
presence of these proteins, 2,000 copies within a single cell is a relatively high concentration (mi-
cromolar order) (22, 35, 36). However, if the cell contents are spilled out into microchambers with
volumes in the 0.1–1-nL range, 2,000 protein copies translates into a 3–30-picoM concentration,
which can push the limits of many ﬂuorescent enzyme-linked immunosorbent assays (ELISAs).
This highlights the need for strict attention to assay conditions. It isn’t just about the antibodies!
Surface chemistry also plays important roles. Phosphoproteins, such as p-EGFR and p-ERK, can
be parts of the same intracellular signaling network. For example, activation of EGFR (to form
p-EGFR) can, in turn, lead to ERK phosphorylation. Thus, ERK is called a downstream effector
of EGFR. The implication is that the abundance of p-ERK within a cell will be positively inﬂu-
enced by the abundance of p-EGFR. Quantifying such protein relationships is an important piece
of what is captured in a multiplexed single-cell functional proteomics assay.
The last protein, VEGF, is a secreted growth factor and a ligand for the VEGF receptor
(VEGFR). It is associated with normal tissue function, but it is also associated with promoting
angiogenesis in many solid tumors. From a detection standpoint, VEGF is similar to TNF-α, al-
though, in hypoxic tumors, its production is often associated with the transcription factor hypoxia
inducible factor (37). Thus, for certain single-cell studies, it may be desirable to simultaneously
monitor VEGF secretion levels and phosphoprotein signaling pathways. This highlights the in-
teresting challenge of monitoring multiple classes of proteins (secreted, cytoplasmic, membrane)
from the same single cells.
3. HISTORY OF NON-MICROCHIP SINGLE-CELL
PROTEOMICS TOOLS
Single-cell proteomicsmethods have evolved overmore than 50 years, dating back to the invention
of the Coulter counter (38), which evolved into the ﬁrst cytometers (39). The emergence of lasers,
photon detectors, high-speed electronics, bioconjugation chemistries, and dye molecules fed into
the development of ﬂuorescence ﬂow cytometry (FFC) (40), ﬂuorescence-activated cell sorting
(FACS) (41), and ELISpot (21). Most recently, mass spectrometry advances have been harnessed
for the development of mass cytometry (42). Excepting ELISpot, the dominant applications of
these tools have been for sorting or enumerating cellular phenotypes based on measurements of
surface marker (membrane) proteins. Intracellular staining (ICS) techniques have opened FFC
and mass cytometry up to the analysis of at least a few cytoplasmic functional proteins per cell.
Each of these techniques has strongly inﬂuenced the development and/or the speciﬁc applications
of the more recent microchip tools.
3.1. The Enzyme-Linked Immunosorbent Spot Method
ELISpot intrinsically assays for functional proteins (43). The cells of interest (typically immune
cells) are localized on a plate using surface-bound capture antibodies against speciﬁc cell surface
markers. That surface is also coated with capture antibodies against speciﬁc secreted proteins.
When the bound cells secrete proteins, ﬂuorophore-labeled secondary antibodies are employed
to bind to those captured proteins and provide a readout. By spatially correlating ﬂuorescent
spots with the locations of attached cells, the fraction of cells that are active secretors is recorded.
280 Yu et al.
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ELISpot assays are colorimetrically limited to the detection of approximately three proteins,
but even with this limitation, ELISpot assays have been broadly used for monitoring immune
system activation, most commonly by monitoring IFN-γ release (see, e.g., 44, 45). However,
other functions, such as cell-mediated cytotoxicity, can be tracked via ELISpot assays of GB
and other cytotoxic granules (46). ELISpot assays have provided several important lessons. First,
secreted proteins from single cells may be readily detected with standard, sandwich-type ELISAs
(47, 48). Second, well-deﬁned immune cell phenotypes can be functionally heterogeneous. Third,
ELISpot assays begin to hint at the importance of immune cell function, relative to immune cell
population abundance, in terms of understanding various disease processes.
3.2. Multicolor Fluorescence Flow Cytometry, Fluorescence-Activated
Cell Sorting, and Mass Cytometry
FFC and FACS are the dominant workhorses for single-cell proteomics. They bring a reasonably
high level of multiplexing. Measurements of 6–10 simultaneous parameters per cell are practical,
and analysis of up to 19 or so parameters is possible with highly specialized equipment (49). In this
parlance, two parameters are associated with light scatter (forward and side) for discriminating
between broadly different cell types (e.g., monocytes and platelets). The rest of the parameters
are colorimetric, typically associated with different membrane proteins that are assayed using
ﬂuorophore-labeled antibodies. A triumph of modern biology has been the identiﬁcation of cell
surface markers that allow, by FACS, the enumeration and sorting of speciﬁc cellular phenotypes
from blood or tissues. For example, a cytotoxic T cell is deﬁned by the cell surface markers cluster
of differentiation (CD)3, CD45, and CD8, with additional markers specifying the antigen speci-
ﬁcity of the T-cell receptor (TCR) or providing further phenotypic classiﬁcation, such as effector
memory (50). Mass cytometry, which was recently developed by Nolan’s (42) group, extends the
concept of FFC to a substantially higher level of multiplexing through the use of antibodies that
are tagged with mass labels, rather than ﬂuorophore labels. Measurements of up to 34 parameters
at the single-cell level (binding of 31 antibodies, cell viability, DNA content, and relative cell size)
(42) have been reported. The power of ﬂow cytometry tools to sort speciﬁc cell types and to even
help deﬁne immune cell differentiation (42, 49–51) has strongly inﬂuenced our basic picture of the
immune system and how it functions in response to speciﬁc threats. Not coincidentally, immune
cell biology has provided an important scientiﬁc driver for the development of microchip-based
single-cell proteomics.
Protein cell surface markers permit the sorting of cellular phenotypes from broad populations,
but analyzing the functional performance of those phenotypes requires assays of functional pro-
teins. For immune cell functions, these are normally secreted proteins that mediate the tasks of
target killing (GB), self-renewal [interleukin (IL)-2 for T cells], recruitment of other immune cell
types, inﬂammation (IL-6), and immune system regulation (IL-10), etc. The relative levels of a
few (typically two to ﬁve) of these proteins may bemonitored through the use of ICS FFC (52, 53).
ICS FFC involves ﬁrst blocking protein secretion and then ﬁxing and making permeable the cells
to allow for perfusion of antibody-labeled dyes. Although the blocking of protein secretion is a
signiﬁcant perturbation, much has been learned using ICS FFC. Examples include an understand-
ing of the inﬂuence of pathogens toward steering functional diversity in phenotypically deﬁned
populations, as well as the importance of the speciﬁc nature of that functional diversity in immune
responses to speciﬁc threats. Using similar cell staining protocols (54, 55), ICS FFC has also been
utilized to investigate the structure of phosphoprotein signaling pathways (36, 56, 57). Those
studies, which are almost exclusively from Nolan’s (42) group, have been limited in number but
highly informative. This highlights both the importance and difﬁculty of such investigations (58).
www.annualreviews.org • Single-Cell Functional Proteomics 281
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Again, ﬂow cytometry methods have helped deﬁne the opportunity for using single-cell functional
proteomics to elucidate phosphoprotein signaling pathways, and this has inﬂuenced applications
in corresponding microchip tools.
4. MICROCHIP-BASED SINGLE-CELL PROTEOMICS METHODS
These tools use either antibody staining of the investigated cells (similar to ﬂow cytometry or ICS
FFC) or surface-based immunoassays (similar to ELISpot) to measure proteins released from the
cells.Within these two primary classes, there are further differentiators; some tools permit control
over the chemical environment around each of the assayed cells, whereas others analyze cells that
are physically, but not chemically, isolated. This is an important distinction, because control over
the chemical environment surrounding a cell can yield a screening tool. Almost all of the tools
permit the cells to be visualized using microscopy, and so certain parameters, such as cell size and
cell morphology, are basically a given.
4.1. Tools Using Cellular Staining Assays
Early generation microﬂuidics-based single-cell proteomics platforms were essentially miniatur-
ized versions of FACS tools. For example, Quake’s (59) group developed a micro(μ)-FACS chip
for separating green-ﬂuorescent protein-expressing Escherichia coli cells from a mixed population
of nonﬂuorescent and ﬂuorescent bacteria. The design used programmable ﬂow conditions to
switch ﬂow directions and permit the cell types to be directed into different collection chambers.
An enabling conceptual advance was the earlier development of integratedmicroﬂuidics platforms
that incorporated valves, mixers, microchannels, andmicrochambers onto the samemicrochip (1).
This design ﬂexibility has been adapted for some of the recent microchip proteomics platforms
and has also been important in the development of tools for single-cell transcriptome analysis (3).
Other variations have emulated the concepts of ICS FFC. Sun et al. (22) utilized multicolor anal-
ysis of ﬂuorescent antibody-labeled cytoplasmic proteins to assay for six parameters from single
cells (binding of four antibodies and cell size and DNA content) from several human brain tumor
biopsies. Using ﬁxed and permeable cells, they stained for the proteins EGFR, p-Akt (protein
kinase B), p-S6k, and phosphatase and tensin homolog. These proteins are associated with the
phosphoinositide 3-kinase/Akt/mammalian target of rapamycin (mTOR) signaling pathway that is
hyperactivated inmany cancers, includingmany brain cancers. This type of analysis requires much
smaller sample sizes than are needed for ﬂow cytometry, and themicrochip platforms are also rela-
tively inexpensive. Gerdes et al. (60) reported on a sequential staining procedure of formalin-ﬁxed,
parafﬁn-embedded tissues that permitted a high level (∼60 parameters) of multiplexing in what
was effectively an advanced immunohistochemical staining approach that permitted some analysis
at the single-cell level.
Virtually all other microﬂuidics single-cell proteomics tools utilizing cellular staining also
separate the cells prior to analysis. One set of platforms, called cell arrays (19, 35, 61), uses arrays
of micropatterned structures (microhurdles) to catch cells from a ﬂowing single-cell suspension.
The cells are physically separated, but not chemically isolated, from each other.Without chemical
isolation, cell array assays yield information similar in nature to ELISpot assays, or even single
parameter ICS FFC, in that the percentage of cells expressing a particular protein is measured
(Figure 1). That (a) the chemical treatment to ﬁx and perfuse cells with labeled antibodies is
readily automated and quite rapid and that (b) very small numbers of cells are needed relative to an
ICS FFC assay are inherent advantages to cell arrays. Eyer et al. (62) reported on a variation of cell
arrays inwhich cellswere captured in the types ofmicrohurdles shown inFigure 1a,b; however, the
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design permitted additional control over the chemical environment of the cells, although it did not
allow for such control at the single-cell level. Those workers developed a ﬂuorescent readout assay
for detecting the enzymeNAD(P)H oxidase from single cells, and applied it towardmeasurements
of single-cell enzyme kinetics for speciﬁc biomolecular processes. Cell array experiments typically
allow on the order of 102 single-cell assays.
Microdroplets (63) provide a related approach but one that permits control over the microen-
vironment surrounding each cell (18). To date, there is not much literature in this area, although,
with additional development, the concept might evolve into a viable screening approach. Con-
trol over the local chemical environment surrounding each cell is a distinguishing characteristic,
because it can permit experiments that are hard to envision with ﬂow cytometry or ELISpot.
Microdroplets also permit assays on quantized cell populations and, through calibration with ﬂu-
orescently labeled beads, microdroplet immunoassays can yield absolute quantitation of protein
copy numbers (64). Such calibrated assays, however, have not been applied to single cells but only
to very small volumes of cell lysate.
4.1.1. Cell staining platforms: looking to the future. Those microchip platforms that rely
on cell staining typically assay for one or two proteins per cell, although this limitation is not
fundamental. Multicolor excitation and imaging techniques, coupled with modern dyes, should
permit higher levels of multiplexing; however, they would also add much of the expense and
sophistication of multicolor FFC but without the beneﬁt of cell sorting. A more attractive option
might be to use the imaging access afforded by these microchip tools to integrate super resolution
imaging (65) with a conceptual extension of optical barcodes (66). For the barcoding, an antibody
would be labeled with a long ssDNA oligomer. That DNA, in turn, is hybridized with short-
chain, complementary ssDNA oligomers to which dyes are attached. Super resolution imaging
can permit the spatial resolution of dye labels. Thus, with n colors and p dye positions, one
can generate sufﬁcient barcodes to detect np different proteins. This concept could rapidly yield
multiplexing numbers that approach the size of the proteome. Although such an experiment is
not currently practical, it provides at least a starting point for discussions regarding meeting the
grand challenge of measuring the entire proteome within a single cell.
4.2. Tools Using Surface-Based Immunoassays
Tools using surface-based immunoassays are conceptually similar to ELISpot but have capabil-
ities that can in many ways surpass those of cytometry tools. Separating protein assays from the
cell implies that individual proteins can be spatially, rather than colorimetrically, identiﬁed, and
that sandwich ELISA-type assays can be used. Of course, cell staining of proteins still can be
simultaneously carried out. The result is a signiﬁcantly higher level of multiplexing and, for some
proteins, absolute quantitation. Second, intracellular, membrane, and secreted proteins may be
assayed from the same single cell. Third, the chambers in which the cells are isolated can po-
tentially accommodate multiple cells and/or cell types, thus permitting measurements of cellular
interactions. Finally, these platforms allow the integration of functional assays (e.g., cell motility)
with protein assays. In this class of platforms, only two base technologies—the microengraving
technique from Love’s group and our own SCBCs—have been reported, but both have been
widely applied. We discuss the microengraving platforms ﬁrst.
4.2.1. Microengraved single-cell proteomics chips. Figure 2 employs an array of nearly 105
microwells to isolate and culture single cells and quantized cell populations. A microengraved
(antibody-coated) substrate is used to cap the microwell array and to capture secreted proteins.
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Figure 2
Cell array device applied for the rapid ﬁxing and treatment of cells for staining intracellular phosphoproteins, applied here to illustrate
the inﬂuence of the BCR/Abl and SRC tyrosine kinase inhibitor Dasatinib on patient-derived CD34+ stem cells. (a) The cell array
device. A single-cell suspension is introduced at the inlet, in which individual cells are trapped by specially designed microhurdles that
permit liquid reagents to ﬂow through. Once trapped, the cells can be rapidly ﬁxed, permeabilized, and stained with phosphospeciﬁc
antibodies. (b) Patient-derived stem cells pretreated with Dasatinib and then stained for the functional proteins p-SRC (top) and
p-STAT5 (bottom), with and without Dasatinib treatment. The individual panels represent (i ) bright ﬁeld, (ii ) ﬂuorophore-conjugated
anti-p-SRC (or p-STAT5) IgG, (iii ) Annexin-V-Cy5 (top) or Sytox green (bottom), and (iv) merged images. (c) Statistical comparisons
between the on-chip assays and analogous assays using ICS-FFC. Figure adapted from Reference 35. Abbreviations: FFC, ﬂuorescence
ﬂow cytometry; ICS, intracellular staining; STAT, signal transducer and activator of transcription.
Those proteins are assayed using sandwich ELISAs, and up to three secreted proteins are simulta-
neously detected using colorimetric discrimination. Thus, the approach is similar to ELISpot but
with a few important distinctions. Much higher statistics are achievable, the cells are chemically
isolated, and the microengraved substrate can be replaced in situ. Replaceable substrates enable
single-cell kinetic studies (67). Substrate removal also allows access to speciﬁc cells, identiﬁed from
the proteomics assays, for subsequent analysis or culture formation (68). Both of these advantages
are very hard to replicate using ﬂow cytometry tools. An additional advantage of the microen-
graving platform is that it can be modiﬁed for PCR-based detection of a few transcripts at the
single-cell level (69), although the combination of proteins and transcripts from the same single
cells, using microengraved platforms, has not yet been reported. Figure 3 illustrates a microen-
graving experiment designed to detect antibody-secreting B cells collected from speciﬁc locations
from a healthymouse or amousemodel of the autoimmune disorder known as Sjo¨gren’s syndrome
(68). B cells are analyzed, using the microengraved slide, for their production of antibodies and
for the speciﬁcity of those antibodies against speciﬁc antigens. If certain of the B cells exhibit
particularly interesting behavior, they can be recovered for further culture or analysis.
4.2.2. Single-cell barcode chips. SCBCs are versatile and information-rich tools in which single
cells, or deﬁned numbers of cells, are isolated within microchambers that each contain a many-
element antibody array (the barcode). A fewhundred to 104 individualmicrochambers are included
within a single microchip. Depending on the application, microchamber volumes are between 0.1
and 2 nL (26, 28), and microchamber design and operation protocols can permit sandwich-type
ELISA immunoassays of cytoplasmic, secreted, or membrane proteins with a measurement error
of ∼10% for a given protein level (29).
Standard protocols may be used for microchip construction, but the patterning approach for
the antibody barcode has unique constraints. The barcode is the enabling SCBC technology;
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Figure 3
A microengraving experiment designed to capture and characterize antibody-secreting B cells reacting
against salivary gland tissues in SjS (an autoimmune disease). (a) Process ﬂow of experiment. (b) Micrograph
of a portion of a nanowell array and microengraving assay results for the indicated microwell containing a
single B cell. The cells are stained with calcein (live cells), FITC-dye-labeled CD19 and Cy7-dye-labeled
CD4. The data presented for the live cell indicate production of antibodies that exhibit reactivity against SjS
gland antigens. (c) Statistical analysis of the percentage of IgG1 producing B cells for both normal and
SjS-susceptible mouse models. Adapted from Reference 68. Abbreviations: FITC, ﬂuorescein isothiocyanate;
PDMS, polydimethylsiloxane; SjS, Sjo¨gren’s syndrome.
as such, we discuss it in some detail here. Because of the instability of antibodies for long-term
storage, or toward microchip processing conditions, the barcodes are initially patterned as ssDNA
barcodes, with each barcode stripe having a unique ssDNA label. A cocktail of antibodies labeled
with complementary ssDNA′ oligomers is used to convert the DNA barcode into an antibody
barcode, just prior to running an assay (70–72). The microchamber surface area available for a
typical 20-element barcode is between 150× 150 μm2 and 1,000× 150 μm2, implying each array
element needs to be approximately 10–20 μm wide, at a 20–40-μm pitch. Such dimensions may
be read with a standard array scanner (73) but are beyond the resolution of standard spotting tools
(74). Molecular patterning tools that can approach these dimensions include molded elastomer
stamping (75, 76), dip pen lithography (77), andmicroﬂuidic ﬂowpatterning (78).Of these choices,
stamping does not permit the required level of multiplexing, whereas dip pen does not yield a
surface coverage sufﬁcient for stable and sensitive assays. Thus, we have developed microﬂuidic
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ﬂow patterning into the method of choice for SCBCs, including even building robotics systems to
automate the task (79). In Figure 4 we provide data showing the inﬂuence of various barcoding
surface chemistries on assay sensitivity, some of which are described in Reference 20. Details of the
ssDNA oligomers and antibody pairs used in SCBCs can be found in the supplementary materials
of numerous publications (2, 28, 30, 80). The ﬂow patterning approach described in Figure 4 can
be modiﬁed for doubling the density of the antibody arrays (26, 81).
Figure 5 depicts an SCBC microchamber designed for assaying phosphoprotein signaling
pathways from single cells, along with representative data from such an assay. A full SCBC data
set may contain 20 or more assayed proteins (R. Fan, unpublished data) and is recorded as a table.
Each row corresponds to a microchamber address, and the columns contain the numbers and
locations (or other descriptors) of cells within that microchamber, as well as the assayed levels of
the individual proteins.
5. BIOLOGICAL AND BIOMEDICAL APPLICATIONS
5.1. Immunology and Immune Monitoring
Because of the variety of potential pathogen targets, cellular immunity is functionally heteroge-
neous, which is a characteristic uniquely quantitated at the single-cell level.Many efforts to capture
this heterogeneity have used ICS FFC. An example is the work of Betts et al. (82), who measured
ﬁve functions (degranulation and levels of IFN-γ, macrophage inﬂammatory protein 1b, TNF-α,
and IL-2) from single HIV-speciﬁc CD8+ T cells collected from chronically HIV-infected indi-
viduals and showed that the number functions (the polyfunctionality) were inversely correlated
with viral load in those patients. Newell et al. (51) used ICSmass cytometry to assay 17 membrane
protein markers, 6 intracellular cytokines, and 2 cytotoxic granules from stimulated CD8+ T cells
from healthy patients. They found an almost combinatorial distribution of cytokine secretion
proﬁles across the individual cells, but there were distinct niches occupied by virus speciﬁc cells.
Microﬂuidic platforms have also been used to address the question of functional heterogeneity
in cellular immunity. Ma and coworkers (28, 80) reported on the longitudinal monitoring of
patients undergoing TCR-engineered adoptive cell transfer (ACT) cancer therapy (83). This
cell-based immunotherapy was for the treatment of metastatic melanoma. SCBCs were used to
compare the functional diversity of tumor antigen (MART-1)-speciﬁc CD8+ T cells collected
from the blood of melanoma cancer patients with CD8+ T cells collected from healthy donors.
They combined 19-plex SCBC functional (secreted) protein assayswith 10-color FACS tomeasure
the functional evolution of speciﬁc T-cell phenotypes at 5 to 10 time points over a 90-day trial.
These measurements led to several conclusions. First, for a given patient and T-cell phenotype,
if all single-cell data from all time points were coanalyzed, a level of functional coordination was
resolved,meaning that theT cells could be loosely classiﬁed according to biological behaviors, such
as antitumor or proinﬂammatory behaviors. Second, the most polyfunctional cells dominated the
immune response: Roughly 10% of the cells of a given phenotype secreted ﬁve or more different
proteins and, for any one of those proteins, those highly functional cells secreted, on average,
100-fold more protein copies than the less polyfunctional cells. Thus, for a given phenotype,
10% of the cells dominated the overall immune response by tenfold. This led to the deﬁning
of a polyfunctionality strength index. Interestingly, although the cellular population dynamics or
phenotype changes (such as naı¨ve or central memory) over the course of the trial did not yield
clear clinical correlates, the polyfunctionality kinetics did correlate with clinical observations,
providing feedback for potentially improving the ACT trial design. This collective work over the
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Figure 4
The surface chemistry of DNA barcode patterning and its importance for quantitative single-cell protein
immunoassays. (a) The microﬂuidic ﬂow patterning template used to prepare barcodes on PLL-coated glass
slides. (i ) The elastomer ﬂow patterning mold contains one channel for each barcode stripe, and a mold for a
20-element barcode is drawn. The channels meander across the glass surface and are on the order of 1 m
long and 10–20 μm wide, depending on the design. (ii ) ssDNA oligomers are initially patterned, and the
quality of those DNA barcodes is assessed by hybridizing each strand with a complementary, dye-labeled
ssDNA′ oligomer. (iii ) The digitized ﬂuorescence micrograph shows the uniformity of a 10-element barcode
across the region indicated by the yellow bar in ii. (b) Digitized ﬂuorescence data reﬂect the DNA loading of
20-μm-wide barcode stripes, based on various patterning chemistries. O means that the indicated chemistry
was used, and X means that it was not used. CV values reﬂect the loading uniformity of the various
patterning strategies. Surface chemistry deﬁnitions for panel b: On-chip PLL treatment: 0.1% PLL solution
in PBS ﬂows through the microchannels before DNA loading to increase the amount of amine groups that
are used to immobilize DNAs. Dry method: After the channels are ﬁlled with DNA solution, the device is
fully dried within a desiccator. The surface-adsorbed ssDNAs are cross-linked by thermal treatment (at 80◦C
for 4 h). Covalent method: A linker molecule that contains an amine-reactive NHS ester at each end of an
eight-carbon spacer arm is used to immobilize amine-terminated DNAs to the PLL surface. (c) Calibration
data for the protein p-ERK, measured using the various chemistries. Surface chemistry improvements yield
more than a tenfold increase in assay sensitivity, enabling single-cell assays of both highly challenging
primary tumor cells (the GBM patient sample) and model cell lines. Some of these data follow protocols
outlined in Reference 20. Abbreviations: CV, coefﬁcient of variation; ERK, extracellular signal-regulated
kinase; GBM, glioblastoma multiforme; NHS, N-hydroxysulfosuccinimide; PBS, phosphate buffered saline;
PLL, polylysine.
www.annualreviews.org • Single-Cell Functional Proteomics 287
A
nn
ua
l R
ev
ie
w
 o
f A
na
ly
tic
al
 C
he
m
ist
ry
 2
01
4.
7:
27
5-
29
5.
 D
ow
nl
oa
de
d 
fro
m
 w
w
w
.an
nu
al
re
vi
ew
s.o
rg
 
A
cc
es
s p
ro
vi
de
d 
by
 C
al
ifo
rn
ia
 In
sti
tu
te
 o
f T
ec
hn
ol
og
y 
on
 0
3/
06
/1
5.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
AC07CH13-Heath ARI 24 June 2014 7:17
Lysis/buffer
inlet
Pressure inlets
for valve control
Reagent/
cell inlet
d
a
***
**
0
80
In
te
ns
it
y 
(a
.u
.)
Cells per chamber
p-P70S6k p-mTOR
60
40
20
1 1 22 33
***
** e
15,000
1,500
150
150 1,500 15,000
Co
py
 n
um
be
rs
 p
-E
G
FR
Copy numbers p-ERK
Capture antibody microarray
Valve B closed
3
Valve A closed
Cell lysis and incubation
Valve B closed
Cell lysate
5
Valve A closed
Detection antibody and
fluorescent probe
6
All valves open
c
Lysis buffer channel
Cell chamber
Valve for lysis buffer
b
Figure 5
SCBC images, assay process ﬂow, and representative data for assaying a panel of phosphoproteins from single cells. (a) A photograph of
a 320-microchamber chip (a penny at bottom left provides scale) and (b) a higher resolution image of a single microchamber from that
chip. The functional regions are colored with food dyes. (c) Process ﬂow for capturing intracellular proteins. Cells are loaded onto the
chip in the upper halves of the microchambers, and lysate buffer, with phosphatase and protease inhibitors, is loaded into the bottom
halves. For assaying secreted proteins, the cells are incubated on-chip for a few hours. Otherwise, the microchip is cooled to 0◦C, and
valve B is opened for 30 min to diffuse lysis buffer into the upper chamber. The valve is closed, and the microchip is kept at room
temperature for 2 h to permit capture of the released proteins. The SCBC is then ﬂushed, and a cocktail of detection antibodies and
ﬂuorescent probes is introduced to develop the barcodes. The SCBC is disassembled to permit digitization of the barcode ﬂuorescence
using an array scanner. (d ) Scatter plots of one-, two-, and three-cell protein assays of p-P70S6k and p-mTOR, as measured from the
model GBM cell line U87EGFRvIII. Each dot is a single experiment, and the y-axis shows ﬂuorescence intensities collected from a
digitized barcode. The increase in average signal level (black bars) as the numbers of cells increase indicates that the measured protein
abundances likely lie just below the linear response regime of the ELISA. (e) A scatter plot showing the correlation between two assayed
proteins. Each dot represents a single experiment; red dots represent one-cell data and blue dots zero-cell data (background). Panel e is
adapted from Reference 26; panels a–d are adapted from Reference 30. Abbreviations: ELISA, enzyme-linked immunosorbent assays;
ERK, extracellular signal-regulated kinase; GBM, glioblastoma multiforme; SCBC, single-cell barcode chip.
past decade has reﬁned the notion that the quality of a T-cell immune response is best captured
by the functional performance of the T cells, rather than by their quantity (84).
Most reported applications of the microengraving platform have also focused on immunology
(25, 67, 85–89). These investigations have emphasized types of experiments that are not tractable
using the various cytometry methods. The ﬁrst is the ability to replace, in situ, the microengraved
slide that contains the immunoassays, thus permitting investigations of the kinetics of protein
secretion (67, 89) from single activated T cells. Those studies resolve individual T cell secretion
trajectories and have provided a higher resolution picture of T cell kinetics than can be captured
by more traditional means (34, 90). A second aspect of the microengraving studies has been to
identify immune cells with interesting functional properties and then ﬁnd ways to separate those
288 Yu et al.
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cells for additional investigations (68, 88). Those studies are particularly interesting from the
point of view of identifying antigen-speciﬁc cells (e.g., B cells or T cells). Such cells, although
often difﬁcult to isolate, play important roles in immune responses (91) or in therapies that rely on
encouraging or engineering (92) such responses against disease-speciﬁc antigens. The microen-
graving platform may provide a viable approach toward identifying and characterizing these rare
cells.
5.2. Phosphoprotein Signaling Pathways
For many cancers, genomic surveys are revealing a landscape of altered signal transduction cas-
cades that often cluster along a set of druggable core pathways. In fact, these pathways contain
molecular targets for newer generations of cancer therapies (14). However, the translation of ge-
nomic data into effective clinical treatments has been confounded because nongenetic cell-to-cell
variability is profound in drug responses and resistance development. A recent editorial (93, p. 2)
has pointed out that capturing the functional protein signaling networks may prove valuable for
this purpose, because those signaling proteins, “not the genes per se, are responsible for the pheno-
types of tumors and for the emergence of therapeutic resistance.” Single-cell proteomics provides
the most direct approach for elucidating protein signaling network structure and coordination,
and information from such measurements emerges at many levels. First, the spread (variance) in
copy numbers of a given protein, as measured across each of many otherwise identical single cells
(see Figure 1 or Figure 5d ), can represent the functional heterogeneity of that protein. Popula-
tion heterogeneity can arise from factors such as the stochastic nature of intracellular events (94)
controlled by low-copy-number transcription factors (95) or through cell–cell interactions (95,
96). The net result may be high-amplitude ﬂuctuations at the single-cell level but stability across
a population (97). In other words, the population is stable exactly because it is heterogeneous
(consider, for example, the robust nature of a diverse economy). This concept can be quantiﬁed
using statistical physics models. Thus, ﬂuctuation measurements can capture cellular heterogene-
ity, while simultaneously providing a measure of the stability of the organelle, tumor, etc., that
is comprised of those cells and providing a bridge to statistical physics models with predictive
capacity. This approach contrasts with traditional biology thinking, which might seek to classify
the population into functional phenotypes. Such thinking discards the heterogeneity of the system
in favor of a more streamlined (but ultimately nonpredictive) description.
A second level of information involves protein–protein correlations (Figure 5e). Correlations
and anticorrelations can imply activating and inhibitory interactions. This means that measure-
ments with higher multiplexing capacity will capture larger numbers of such interactions and thus
increasingly resolve the associated protein signaling network (29, 57). The use of physicochemical
laws to predict biological behaviors based on single-cell proteomics assays has been studied by
Shin et al. (98) to investigate (and predict) how stimulated macrophage cells respond to various
perturbations. More sophisticated, but related, approaches were applied to study the inﬂuence of
hypoxia (reduced O2 partial pressure) on glioblastoma multiforme tumors (30). For that study,
highly speciﬁc and surprising predictions of hypoxia-dependent therapy resistance were made re-
garding the use of mTOR inhibitors to treat both cell lines and tumor models. Those predictions
were veriﬁed.
Assays in which measurements of both cellular function and functional protein levels are exe-
cuted from the same single cells represent experiments that are unique to themicrochip platforms.
Lu et al. (24), using a platform that wasmore or less an SCBC-microengraving hybrid, investigated
a panel of 14 different secreted proteins, as well as motility assays, on model cancer cells, with
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additional extensions to primary cells derived from patient brain tumors. They identiﬁed three
speciﬁc secreted proteins that correlated with cell motility.
5.3. Cell–Cell Interactions
A unique aspect of microchip platforms is that they can permit investigations of quantized cell
populations. Such explorations have focused, at varying levels of resolution, on the inhibitory or
activating nature of intercellular interactions and have combined protein assays with functional
observations (99–102). A recent study (26) correlated the levels of a panel of phospho- and secreted
signaling proteins inmodel glioblastomamultiforme (brain cancer) cells, with cell–cell distances in
two-cell assays. The work revealed that a detailed knowledge of pairwise cell interaction functions
could be used to predict speciﬁc properties of larger cell populations. Such experiments again draw
from concepts derived from statistical physics (103) andmay eventually allow complex phenomena
within tissue microenvironments to be understood.
Although not exactly single-cell work, Shao et al. (104) reported on protein typing of individual
circulating microvesicles using a novel microchip/nuclear magnetic resonance system. Microvesi-
cles (105) are signiﬁcantly smaller than the cells that they originate from and can provide amedium
for cell–cell communication (106) but may also provide a rich source of circulating tumor mark-
ers. This can be especially informative for intracranial tumors, which do not shed cells into the
circulatory system.
Yamanaka et al. (27) utilized a microengraved platform to investigate the interactions between
lymphocytes known as natural killer (NK) cells and target cells. NK cells can recognize and kill
certain cells (such as viral infected cells) without the need for antigen recognition. The workers
found thatNK cells operate independently and promptly when lysing a single target cell. They also
found that IFN-γ secretion correlates with low motility for NK cells that have contacted a target
cell. These types of cell–cell interaction studies may eventually lead to an improved understanding
of the functional heterogeneity of the immune system.
6. LOOKING TO THE FUTURE
Powerful tools such as mass cytometry have appeared over the past few years, but new classes
of microchips for single-cell functional proteomics have also emerged with distinct and powerful
advantages that are just now being explored.With such a rapidly developing ﬁeld, looking into the
future is tricky.One approach is to consider the low-hanging fruit, the technology bottlenecks, and
the biological and clinical drivers that are pushing the ﬁeld forward. For example, all the pieces
currently exist to permit highly multiplexed transcriptome and proteome analyses of the same
primary single cells; as such, this is a low-hanging fruit. The rapid advances of immunotherapy
will likely push the development of such multilevel assays toward those that can identify and clone
the very rare cells that produce particularly interesting antibodies or TCRs. Another clinical
driver is the increase in the development and use of targeted cancer therapies, coupled with the
confounding modest performance of those drugs that is often seen in the clinic. Bridging that gap
will require resolving, at an unprecedented level, the structure of the phosphoprotein signaling
networks that are targeted by those therapies.
A technical bottleneck involves the level of multiplexing achievable using current approaches.
Both cytometry and microchip tools likely reach a limit between 50 and 100 proteins per cell.
Even beating this limit by a factor of two or three would still represent sampling only a tiny part
of the proteome. This limit arises because of the reliance on antibody-based detection schemes.
Beating this limit will require either (a) a protein capture agent technology that is the equivalent
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of very cheap, robust, and very high performing monoclonal antibodies or antibody-equivalents
or (b) a discovery approach, such as mass spectrometry, for single-cell proteomics.
Finally, an increased emphasis on accurate and quantitative measurements will clearly push
the ﬁeld forward, simply because of the transportability of such measurements for comparisons
across cell lines, patient samples, etc. This is a lesson drawn from the current revolution in mass
spectrometry proteomics. Focused proteomics tools such as multiple reaction monitoring (107),
coupledwith the existence of the human peptide atlas (108), have broughtmass spectrometry to the
point where it is now being developed as a truly quantitative clinical diagnostics tool for measuring
panels of protein biomarkers. The strong emphasis on quantitative and accurate measurements
highlights the role of analytical chemistry for this ﬁeld.
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